Overview of Anthelmin Plus

What is Anthelmin Plus? A Foundational Definition

Property	Description
Active Ingredients	Febantel, Praziquantel, Pyrantel
Form	Oral tablet (Flavoured tablet)
Pharmacological Class	Broad-spectrum anthelmintic (Antiparasitic agent)
General Use	Treatment of mixed internal parasite infestations
Origin	Synthetic chemical derivatives

What Type of Medicine is Anthelmin Plus? (Identity and Classification)

Anthelmin Plus is defined as a veterinary medicinal product that functions as a broad-spectrum anthelmintic, belonging to the general class of antiparasitic agents. The medicine is supplied as an oral tablet, often a flavoured tablet, formulated for simple oral use in its target species. This preparation is distinguished as a fixed combination product, strategically designed to merge three distinct synthetic chemical derivatives into one unit. This strategy is clinically recognized for addressing multiple parasitic classes simultaneously.

What is the Composition of Anthelmin Plus? (Ingredients and Synergy)

The core of Anthelmin Plus lies in its three active ingredients: febantel, praziquantel, and pyrantel. Febantel is a pro-drug that metabolizes into active benzimidazole derivative compounds, while praziquantel is a pyrazino-isoquinoline derivative, and pyrantel is a tetrahydropyrimidine derivative. The strategic blend of these agents achieves synergistic activity, meaning their effect together is greater than the sum of their individual actions. This class of combined products is designed for comprehensive parasite management. This deliberate blending ensures that the parasitic population is attacked through several primary biological pathways simultaneously.

What is the General Purpose of Anthelmin Plus? (Scope and Benefit)

The general purpose of Anthelmin Plus is to provide comprehensive relief from mixed infestations of internal parasitic worms in its target species. The medicine offers a broad spectrum of activity that is specifically formulated to address both of the major classes of intestinal parasites: nematodes (including common roundworms and hookworms) and cestodes (tapeworms). The inclusion of febantel in the fixed combination is a key differentiating feature, ensuring enhanced action against challenging parasites like whipworms. This comprehensive coverage simplifies the necessary management protocol against complex parasitic burdens.

What side effects are possible with Anthelmin Plus?

Possible side effects and safety information

Adverse Reaction Scope

Official regulatory documents classify the documented adverse reactions associated with the Praziquantel, Pyrantel, and Febantel combination into specific system-organ classes. The majority of reported effects are categorized as Very Rare, meaning they are observed in less than 1 out of 10,000 subjects treated, according to the official regulatory frequency framework.

System-Organ Class	Officially Documented Reactions (Very Rare)
Gastrointestinal Disorders	Vomiting (emesis), Diarrhoea
Nervous System Disorders	Lethargy, Hyperactivity

Serious adverse reactions are addressed through contraindications, which are mandatory safety restrictions. The medicine is contraindicated in subjects with a known sensitivity or hypersensitivity to the active ingredients or excipients, signifying a potential for severe immunological response.

Safety-Related Constraints and Special Populations

Official labeling includes explicit restrictions regarding use in specific circumstances and populations:

Piperazine Compounds: The medicine is contraindicated for simultaneous use with piperazine compounds, as this combination may lead to a pharmacological antagonism of effects.
Early Pregnancy: Due to safety data concerning high doses of Febantel in other species, use during the first four weeks of pregnancy is restricted, and the prescribed dose should not be exceeded.
Young Subjects: Safety information includes constraints against use in animals that are less than 3 weeks of age or weigh below a specified minimum threshold.

These safety classifications and constraints are established by government health authorities to formally define the risk profile and mandatory limits of use.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information

Official regulatory documentation addresses the overdose profile by emphasizing the inherent safety margins of the active components, which include febantel, pyrantel, and praziquantel.

Wide Safety Margin: Official summaries note that both benzimidazoles (e.g., febantel) and praziquantel possess a wide safety margin, with praziquantel generally tolerated up to five times the recommended dose.
Low Systemic Absorption: The pyrantel component is noted to have very low systemic absorption, meaning it poses very little danger of toxicity to the host.

When Immediate Medical Help is Required

The primary instruction for seeking medical attention is specific to human exposure:

Accidental Ingestion: In the case of accidental ingestion by a person administering the product, seek medical advice immediately and show the package leaflet or the label to the physician.

This statement defines the critical emergency response for this product, linking urgent care directly to human exposure circumstances. No specific clinical manifestations or symptom clusters are detailed in the official overdose sections, reflecting the components' stated wide safety parameters. Professional consultation should be sought for any concerns related to overdose or unexpected symptoms.

Therapeutic Uses of Anthelmin Plus

What Anthelmin Plus Treats: Main Uses and Benefits

The primary therapeutic use of this medicine is used for managing a broad spectrum of intestinal worms for overall parasite control in its target species. This fixed combination is considered relevant for easing symptoms related to physical discomfort and systemic imbalance associated with parasitic activity.

Therapeutic Scope and Benefits

This medication is commonly used as a broad-spectrum treatment specifically against mixed infestations of internal parasitic worms. It is applied in addressing both tapeworms (cestodes) and the major classes of nematodes, which include roundworms, hookworms, and whipworms. The primary benefit supports the management of these established parasitic organisms, which helps with managing gastrointestinal distress and supports general well-being during symptomatic phases.

Anthelmin Plus is relevant for use in managing parasites that have zoonotic potential, such as the common roundworm. The treatment is also helpful in supporting vulnerable patient groups, including puppies and high-exposure dogs.

“Utilizing this combination supports the patient during difficult episodes by easing distress and is applied across domains where additional symptomatic support is needed.”

Quick Fact: Relevant for managing symptoms related to physical discomfort

Assisting with Zoonotic Risk and Public Health Contexts

The medicine's use in routine deworming programs may assist in limiting the dissemination of infective parasitic stages, which is relevant in managing exposure risk for the surrounding environment and community. This contribution helps with managing the overall systemic burden associated with parasitic presence.

Regulatory References

FDA Drug Label for Praziquantel/Pyrantel Pamoate/Febantel

Eligibility and Restrictions for Use

The official regulatory profile for Anthelmin Plus, a veterinary medicinal product, defines eligibility based on age, weight, health conditions, and reproductive status of the target species: dogs.

Populations for Whom Use is Contraindicated

Category	Official Regulatory Statement
Known Hypersensitivity	Dogs with a known sensitivity to the active substances (febantel, pyrantel, praziquantel) or any excipient.
Concurrent Medication	Must not be used simultaneously with piperazine compounds or other cholinergic compounds.
Age/Weight Limit	Not for use in puppies younger than 2 weeks of age and/or weighing less than 2 kg (or 3 weeks of age / less than 2 lbs, depending on the regulatory document).

Restricted or Allowed Eligibility

Early Pregnancy: Use is formally not recommended in bitches during the first two-thirds of pregnancy (first 4 weeks).
Lactation: The product may be used in nursing bitches.
Eligible Population: The medicine is approved for use in adult dogs and weaned puppies who meet the minimum age and weight requirements, as documented in regulatory monographs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for this medicine is characterized by specific pharmacokinetic and pharmacodynamic restrictions documented in official regulatory sources.

Contraindicated and Non-Recommended Combinations

Co-administration with piperazine compounds is formally contraindicated due to a documented pharmacodynamic antagonism that may lead to reduced efficacy of the pyrantel component. Furthermore, the use of strong Cytochrome P450 3A (CYP 3A) inducers is contraindicated because they can accelerate the metabolism of the praziquantel component, resulting in sub-therapeutic plasma concentrations. The co-administration of other cholinergic compounds is not recommended due to the potential for reinforcing or additive pharmacodynamic toxicity.

Exposure and Administration Constraints

Official labeling for the praziquantel component specifies that strong CYP 3A inducing medicines must be discontinued for a period of two to four weeks before administering the fixed combination, representing a mandatory timing rule to prevent reduced exposure. Regarding non-medicinal substances, the official documents state that the medicine can be administered with food, and no period of starvation or fasting is necessary. Reduced drug clearance, leading to higher and sustained plasma concentrations of praziquantel, is officially documented in cases of liver impairment, a population-specific note that defines an interaction-like risk.

Mechanism of Action

Anthelmin Plus initiates the physiological collapse of target parasites by engaging three distinct, non-overlapping mechanisms focused on muscular function, cellular integrity, and energy reserves.

Disrupting Muscle Control and Ion Balance

Pyrantel acts as a depolarizing agonist on the parasite's nicotinic acetylcholine receptors ( nAChR), inducing immediate spastic paralysis in nematodes. Concurrently, Praziquantel modulates voltage-gated Ca^2+ channels in cestodes, causing a massive, uncontrolled influx of calcium ions ( Ca^2+). This ion overload results in acute muscular hyper-contraction, severe damage to the tegument, and the immediate cessation of movement.

Blocking Energy Production and Cellular Structure

The pro-drug Febantel is metabolized into active benzimidazole derivatives, which bind specifically to the parasite's structural beta-tubulin protein, inhibiting microtubule formation. This disruption prevents the parasite from maintaining cellular transport and absorbing glucose. The resulting mechanistic cascade is the progressive depletion of energy reserves and cellular starvation, leading to irreversible physiological failure for both adult and immature worm forms.

Mechanistic Synergy

The combined action on nAChR, Ca^2+ channels, and beta-tubulin ensures activity across different parasite classes and simultaneously mitigates the risk of single-mechanism resistance. The mechanism of immediate paralysis is complemented by the sustained energy blockade, resulting in comprehensive and irreversible parasitic incapacitation.

Dosage and Administration Information

How to Use Anthelmin Plus: Official Administration Guidelines

The usage of Anthelmin Plus, a combination product containing febantel, praziquantel, and pyrantel, is aligned with standard veterinary guidelines to ensure delivery of the correct dose. The medicine is exclusively for oral administration and is typically supplied as a tablet that may be chewable or flavoured.

Administration and Dosing Schedule

Instruction	Principle of Use	Frequency Pattern
Dose Calculation	Based on the patient's body weight to meet the required minimum dose of each active ingredient (e.g., 15 mg/kg febantel).	Single-dose regimen for established infestation.
Administration Context	May be given with or without food; prior fasting is not required.	Periodic schedule (e.g., typically every three months) for routine adult control.

Population-Specific Use

Administration protocols are modified for young patients due to their specific risk profile. Puppies may commence treatment as early as two weeks of age, with repeat dosing generally scheduled every two weeks thereafter until twelve weeks of age. Subsequent dosing continues on a quarterly schedule. Nursing mothers are also subject to specific dosing cycles two weeks postpartum and continuing every two weeks until weaning, which supports the management of parasite burden in young patients.

Procedural Requirement

Accurate administration necessitates precise measurement of the patient’s body weight to ensure the delivery of the correct number of tablets corresponding to the required dose band. The standard course of treatment for an established parasitic presence is defined as a single, complete administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Anthelmin Plus

Evidence for Use in Mixed Intestinal Parasitic Infestations

This section will summarize the core evidence base, detailing the types of well-controlled laboratory and clinical field studies that explored the evaluation of this medicine against tapeworms and nematodes (including roundworms, hookworms, and whipworms). The content will describe the primary outcomes measured in regulatory trials, such as parasite burden and reduction in egg shedding.

The foundational research includes a mix of well-controlled laboratory efficacy studies and clinical field trials. Study outcomes examined included the direct measurement of Worm Burden at necropsy and monitoring for changes in the amount of Parasite Egg Shedding in samples collected during the study period. Findings describe patterns observed in the studies where measurements related to parasite burden were tracked when the combination was evaluated. Reports cited by regulators provide context related to outcomes across the parasitic species studied.

The research focused primarily on short-term data, and few large-scale, long-term observational studies exist to provide context regarding sustained effects. There is limited information for long-term outcomes, meaning the durability of effect beyond the immediate post-treatment period is not fully established.

Studies on the Management of Other Parasitic Organisms

Research has explored this combination in research settings involving protozoan infections, specifically Giardiasis. Studies used prospective trials, including some Randomized Controlled Trials (RCTs), to evaluate outcomes related to systemic or functional imbalance. Research examined how symptoms evolved in the observed populations, with a focus on measuring the cessation of Cyst or Antigen Shedding in fecal samples.

Trials described variability in reported outcomes across studies. Some studies described patterns related to the evolution of symptoms, and the reappearance of cysts was documented in certain studies. Research is ongoing to determine the most studied duration for this specific application. Furthermore, the evidence highlights what is known and what is still uncertain regarding external factors, such as environmental management.

What is Still Uncertain About Anthelmin Plus

This final section will synthesize the main evidence gaps and areas where additional scientific clarification is needed. Research is ongoing to better understand resistance patterns, as the existing evidence is not uniform across all studies when examining this long-term issue. Furthermore, there is a clear limitation regarding the research that applies to long-term outcomes and the potential for recurrence. Subgroup findings are uncertain for specific treatment approaches.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Anthelmin Plus (FAQ)

Q: Is Anthelmin Plus a type of antibiotic?

Anthelmin Plus is defined in official documents as a broad-spectrum anthelmintic, which means it is an antiparasitic agent. It is not classified as an antibiotic, which is a different type of medicine used specifically to treat bacterial infections.

Q: How quickly do the effects of Anthelmin Plus typically begin after taking it?

The mechanism of action for the medicine's components includes both immediate and progressive effects, according to official information. Two components are described as causing rapid muscle contraction or paralysis in the target parasites. The third component works more progressively by causing long-term energy depletion.

Q: How long does Anthelmin Plus stay in your system?

Information in official product labeling describes the clearance of the components. Regulatory documents show that one component is almost entirely metabolized and excreted rapidly in the urine, while another is typically excreted within 24 hours. The active breakdown products of the third component usually reach their highest concentration in the bloodstream within several hours after administration.

Q: Is a headache a common side effect of Anthelmin Plus?

Headache is not among the specific adverse reactions documented in the official regulatory information. Officially listed side effects are typically related to the digestive system (like vomiting or loose stools) or the nervous system (like lethargy), and these are categorized as occurring in very rare cases.

Q: Is Anthelmin Plus safe to use for an extended period?

The official protocol for this medicine defines it for a single-dose administration for established infestations. For routine control, the treatment is typically repeated at three-monthly intervals. Regulatory documents state that advice should be sought regarding the need for and frequency of repeat treatment.

Q: Is it normal to feel slightly nauseous after taking Anthelmin Plus?

Official information lists both vomiting and diarrhoea as documented adverse reactions in the gastrointestinal system. Although nausea is not explicitly named, these reported adverse effects are typically transient and mild, and occur in very rare cases.

Q: What happens if a person misses a dose of Anthelmin Plus?

For routine adult treatment, the standard course is a single dose. Official documents specify that in cases of heavy parasite infestation, a repeat dose is defined as a treatment protocol administered after 14 days.

Q: Does Anthelmin Plus require a prescription?

The official legal status of supply for this veterinary product often categorizes it as a Veterinary Medicinal Product subject to Veterinary Prescription. The medicine is generally subject to official regulatory control regarding its distribution.

Q: Is Anthelmin Plus gluten-free or suitable for people with allergies?

Official documents list the medicine's excipients (non-active ingredients), which typically include Lactose Monohydrate and Maize Starch. Official documents note that the medicine is contraindicated in individuals with a known hypersensitivity to the active substances or excipients.

Q: Is Anthelmin Plus known to cause drowsiness?

Official adverse reaction lists do not explicitly name drowsiness. However, documented nervous system disorders include lethargy, which is described as a change in activity and alertness, and occurs in very rare cases.

Q: Can Anthelmin Plus be taken on an empty stomach?

Yes, regulatory documents clearly state that the medicine can be administered with or without food. There are no requirements to fast (restrict access to food) either before or after the administration of the product.

Q: How is Anthelmin Plus eliminated from the body?

The active components are primarily processed in the body by the liver and then eliminated. Official information states that the processed products are mostly excreted either in the urine or in the bile.

Q: Are the reported side effects common or rare?

The official regulatory frequency classification for the documented side effects, such as vomiting and diarrhoea, is Very Rare. This means they are expected to be observed in fewer than 1 out of every 10,000 subjects treated.

Q: Does Anthelmin Plus cause changes in mood or behavior?

Official adverse reaction lists include Nervous System Disorders, specifically lethargy and hyperactivity. These effects are considered changes in activity and behavior level and are documented as occurring in very rare cases.

Q: Can Anthelmin Plus be crushed or chewed?

The official instructions indicate that the tablets can be halved or quartered to ensure accurate dosing based on body weight. Regulatory instructions indicate that the tablets can be split to achieve accurate dosing based on body weight.

Q: Is Anthelmin Plus ever used in veterinary medicine?

Yes, Anthelmin Plus is defined in official documents as a veterinary medicinal product intended specifically for use in its target species, dogs.

Q: Are there any known skin reactions associated with Anthelmin Plus?

Official regulatory documents do not list any specific skin reactions in the documented adverse reactions section. The officially documented adverse reactions are categorized under Gastrointestinal Disorders and Nervous System Disorders.

Q: What does 'pharmacokinetics' mean in the context of Anthelmin Plus?

Pharmacokinetics is a scientific term used by regulatory bodies to describe the way the body handles the medicine. It specifically refers to how the drug is absorbed, distributed, metabolized (broken down), and eliminated from the body.

How should Anthelmin Plus be stored and disposed of?

Storage and Disposal Requirements for Anthelmin Plus

The official regulatory documents for this veterinary medicinal product define specific rules for its storage and subsequent disposal.

Storage Conditions and Stability

The unopened product does not require any special storage conditions. The shelf-life of the product as packaged for sale is 3 years. For safety, the medicine must be kept out of the sight and reach of children.

Handling and Disposal

Part-used tablets must be discarded and are not suitable for storage. When disposing of the medicine, it should not be disposed of via wastewater or household waste. Disposal of any unused product or waste materials must be carried out in accordance with local requirements, which includes the use of official take-back schemes.

Anthelmin Plus